R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO
The company also announced that veteran medical device executive Christopher M. Owens will serve as its new President and Chief Executive Officer.
- The company also announced that veteran medical device executive Christopher M. Owens will serve as its new President and Chief Executive Officer.
- The Series B financing was led by affiliates of Deerfield Management with participation from existing shareholders including 415 Capital and a strategic investor.
- R3 Vascular will use the proceeds to support the ELITE FDA IDE pivotal trial of its best-in-class bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD.
- Commenting on the financing and the appointment of Mr. Owens, Jack Springer, Executive Chairman of R3 Vascular said, “On behalf of the R3 Vascular Board of Directors, we are very pleased to complete this exciting Series B financing and welcome Chris Owens as President and CEO.